Amneal Pharmaceuticals (AMRX) Cash from Operations Growth (1y) (2018 - 2026)
Amneal Pharmaceuticals (AMRX) Cash from Operations Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.48 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 425.00% |
| 10 | Amneal Pharmaceuticals | 5.68 Bn | 5.67 Bn | 320.11 Mn | -461.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -461.00% |
| Dec 31, 2025 | 10.36% |
| Sep 30, 2025 | -16.45% |
| Jun 30, 2025 | 111.36% |
| Mar 31, 2025 | 267.98% |
| Dec 31, 2024 | -13.06% |
| Sep 30, 2024 | 74.20% |
| Jun 30, 2024 | 449.55% |
| Mar 31, 2024 | -103.16% |
| Dec 31, 2023 | 683.13% |
| Sep 30, 2023 | -13.02% |
| Jun 30, 2023 | 90.96% |
| Mar 31, 2023 | 16.09% |
| Dec 31, 2022 | -136.82% |
| Sep 30, 2022 | 13.61% |
| Jun 30, 2022 | -141.70% |
| Mar 31, 2022 | -18.76% |
| Dec 31, 2021 | -40.30% |
| Sep 30, 2021 | 83.95% |
| Jun 30, 2021 | -128.97% |